

**Human Pregnane X Receptor  
(NR1I2, PXR, SXR)  
Reporter Assay System**

**3x 32 Assays in 96-well Format**  
Product # IB07001-32

■

**Technical Manual**  
*(version 7.2c)*

**[www.indigobiosciences.com](http://www.indigobiosciences.com)**

3006 Research Drive, Suite A1, State College, PA, 16801, USA

Customer Service:  
814-234-1919; FAX 814-272-0152  
[customerserv@indigobiosciences.com](mailto:customerserv@indigobiosciences.com)

Technical Service:  
814-234-1919  
[techserv@indigobiosciences.com](mailto:techserv@indigobiosciences.com)



## Human PXR Reporter Assay System 3x 32 Assays in 96-well Format

### I. Description

|                                      |   |
|--------------------------------------|---|
| ▪ The Assay System.....              | 3 |
| ▪ The Assay Chemistry.....           | 3 |
| ▪ Preparation of Test Compounds..... | 4 |
| ▪ Assay Scheme.....                  | 4 |
| ▪ Assay Performance.....             | 5 |

### II. Product Components & Storage Conditions .....6

### III. Materials to be Supplied by the User.....6

### IV. Assay Protocol

|                                                         |   |
|---------------------------------------------------------|---|
| ▪ A word about <i>Antagonist</i> -mode assay setup..... | 7 |
| ▪ <i>DAY 1 Assay Protocol</i> .....                     | 7 |
| ▪ <i>DAY 2 Assay Protocol</i> .....                     | 9 |

### V. Related Products.....10

### VI. Limited Use Disclosures.....11

### APPENDIX 1: Example Scheme for Serial Dilutions.....11

## I. Description

### ▪ The Assay System ▪

This assay utilizes proprietary human cells engineered to provide constitutive, high-level expression of the **Human Pregnane X Receptor** (NR1I2), a ligand-dependent transcription factor commonly referred to as **PXR**. PXR is also known as the Steroid and Xenobiotic sensing nuclear receptor (**SXR**).

INDIGO's Reporter Cells express a hybrid form of human PXR. The N-terminal sequence encoding the PXR DNA binding domain (DBD) has been substituted with that of the yeast GAL4-DBD. The native PXR ligand binding domain (LBD) and other C-terminal domains remain intact and functional. Ligand interaction activates the receptor, causing it to bind to the GAL4 DNA binding sequence, which is functionally linked to a resident luciferase reporter gene. Thus, quantifying changes in luciferase activity in the treated reporter cells provides a sensitive surrogate measure of the changes in PXR activity. The principal application of this assay kit is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human PXR.

PXR Reporter Cells are prepared using INDIGO's proprietary **CryoMite™** process. This cryo-preservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells or viability determinations prior to assay setup.

INDIGO's Nuclear Receptor assays are all-inclusive cell-based assay systems. In addition to PXR Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate.

### ▪ The Assay Chemistry ▪

INDIGO's nuclear receptor assay kits capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a  $Mg^{+2}$ -dependent reaction that consumes  $O_2$  and ATP as co-substrates, and yields as products oxyluciferin, AMP,  $PP_i$ ,  $CO_2$ , and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

INDIGO's Nuclear Receptor Assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

### ▪ Preparation of Test Compounds ▪

Small molecule test compounds are typically solvated in DMSO at high concentrations; ideally 1,000x-concentrated stocks relative to the highest desired treatment concentration in the assay. Using high-concentration stocks minimizes DMSO carry-over into the assay plates. Immediately prior to setting up an assay, the master stocks are serially diluted using one of two alternative strategies:

1.) As described in *Step 7* and depicted in Appendix 1 for the reference agonist Rifampicin, **Compound Screening Medium (CSM)** may be used as the diluent to make serial dilutions of test compounds to achieve the desired final assay concentration series.

Alternatively, if test compound solubility is expected to be problematic,

2.) DMSO may be used to make serial dilutions, thereby generating 1,000x-concentrated stocks for each independent test concentration. Treatment media are then prepared using CSM to make final 1,000-fold dilutions of the prepared DMSO dilution series.


Regardless of the dilution method used, the final concentration of total DMSO carried over into assay wells should not exceed 0.4%. Emerging DMSO-induced cytotoxicity can be expected above 0.4%.

*NOTE:* CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup, and that they are considered to be 'single-use' reagents.


### ▪ Assay Scheme ▪

**Figure 1.** Assay workflow.

*In brief*, 200 µl of Reporter Cells is dispensed into wells of the assay plate and pre-incubated for 4-6 hours. Following the pre-incubation period, culture media are discarded and 200 µl/well of the prepared 1x-concentration treatment media are added. Following 22-24 hr incubation, discard the treatment media and add Luciferase Detection Reagent. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



## Human PXR (NR1I2) Agonist Assays



**Figure 2. Agonist dose-response analyses of Human PXR.**

Performance of the human PXR assay using the reference agonists Rifampicin (provided), Hyperforin dicyclohexylammonium (Enzo Life Sciences), TO901317(Cayman Chemical), SR12813 (Tocris), and Mevastatin (Cayman Chemical). Luminescence was quantified and average relative light units (RLU) and corresponding standard deviation (SD) values were determined for each treatment concentration (n = 4). Fold-activation and Z' values were calculated as described by Zhang, *et al.* (1999)<sup>1</sup>. Non-linear regression and EC<sub>50</sub> analyses were performed using GraphPad Prism software. High Z' scores confirm the robust performance of this assay, and its suitability for HTS<sup>1</sup>.

<sup>1</sup> Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.* 4(2), 67-73.

$$Z' = 1 - [3 * (SD^{Control} + SD^{Bkg}) / (RLU^{Control} - RLU^{Bkg})]$$

## II. Product Components & Storage Conditions

This Human PXR Assay kit contains materials to perform three distinct groups of assays in the format of a 96-well plate. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

**Reporter cells are temperature sensitive! To ensure maximal viability the tube of cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in Step 2 of this protocol.**

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inventory the individual kit components be sure to first transfer and submerge the tube of reporter cells in dry ice.

The aliquots of Reporter Cells are provided as single-use reagents. Once thawed, reporter cells can NOT be refrozen or maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

| <u>Kit Components</u>                                               | <u>Amount</u> | <u>Storage Temp.</u> |
|---------------------------------------------------------------------|---------------|----------------------|
| ▪ PXR Reporter Cells                                                | 3 x 0.6 mL    | -80°C                |
| ▪ Cell Recovery Medium (CRM)                                        | 2 x 10.5 mL   | -20°C                |
| ▪ Compound Screening Medium (CSM)                                   | 1 x 45 mL     | -20°C                |
| ▪ Rifampicin, 30 mM (in DMSO)<br>(reference agonist for PXR)        | 1 x 30 µL     | -20°C                |
| ▪ Detection Substrate                                               | 3 x 2.0 mL    | <b>-80°C</b>         |
| ▪ Detection Buffer                                                  | 3 x 2.0 mL    | -20°C                |
| ▪ Plate frame                                                       | 1             | ambient              |
| ▪ Snap-in, 8-well strips<br>(white, sterile, collagen-coated wells) | 12            | <b>-80°C</b>         |

*NOTE:* This Assay kit contains 8-well strips that have been collagen-coated and dried; these strip wells should be stored frozen (-20°C or colder) until use.

## III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

### DAY 1

- container of dry ice (see Step 2)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO<sub>2</sub> incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), or deep-well plates, or appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).
- *Optional:* antagonist reference compound.
- *Optional:* clear 96-well assay plate, cell culture treated, for viewing cells on Day 2.

**DAY 2** plate-reading luminometer.

## IV. Assay Protocol

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on **Day 1**, requiring less than 2 hours of actual bench work plus a 4 hr pre-incubation step. *Steps 12-17* are performed on **Day 2** and require less than 1 hour to complete.

### ▪ A word about Antagonist-mode assay setup ▪

Receptor inhibition assays expose the Reporter Cells to a constant, sub-maximal concentration (typically between  $EC_{50}$  –  $EC_{85}$ ) of a known agonist AND varying concentrations of the test compound(s) to be evaluated for antagonist activity. This PXR Assay kit includes a 30 mM stock solution of **Rifampicin**, a low-potency agonist of PXR that may be used to setup antagonist-mode assays. 3  $\mu$ M Rifampicin typically approximates  $EC_{70-80}$  in this cell-based assay. Hence, it presents a suitable assay concentration of agonist to be used when screening test compounds for inhibitory activity.

Add the challenge agonist (rifampicin) to a bulk volume of **CSM** at an  $EC_{50}$  –  $EC_{85}$  concentration. This medium is then used to prepare serial dilutions of test compounds to achieve the desired respective final assay concentrations. We find that this is an efficient and precise method of setting up PXR antagonist assays, and it is the method presented in *Step 7b* of this protocol.

### **DAY 1 Assay Protocol:** All steps must be performed using aseptic technique.

**1.)** Remove the **2 tubes** of **Cell Recovery Medium (CRM)** from freezer storage, thaw and equilibrate to 37°C using a water bath.

**2.) Rapid Thaw of the Reporter Cells:** *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

*Second*, retrieve **Reporter Cells** from -80°C storage and place them directly into dry ice to transport them to the laminar flow hood: 1 tube for 32 assay wells, 2 tubes for 64 assay wells, or 3 tubes for 96 assay wells. When ready, transfer the tube(s) of reporter cells into a rack and, *without delay*, perform a rapid thaw of the frozen cells by transferring **6.4 ml** of pre-warmed CRM into each tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be **7.0 ml** per tube.

*Third*, during the 5 - 10 minutes incubation period, work in the cell culture hood to *carefully* mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.

**3.)** Retrieve the tube of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.

**4.)** If more than one tube of Reporter cells was thawed, combine them and gently invert several times to gain a homogenous cell suspension. Dispense **200  $\mu$ l / well** of cell suspension into the mounted strip-wells.

*NOTE 4.1:* If INDIGO's Live Cell Multiplex Assay is to be incorporated then 'cell blank' wells (meaning cell-free, but containing 'CSM') must be included to allow quantification of plate-specific fluorescence background (refer to the LCMA Technical Manual).

*NOTE 4.2:* Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling in the reservoir during the dispensing period. Likewise, take care to ensure precision in dispensing exact volumes across the assay plate.

*NOTE 4.3:* Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear, preferably *collagen-coated*, 96-well assay plate. Continue to process this plate in identical manner to the white assay plate.

**5.) Pre-incubate reporter cells:** Place the assay plate into a mammalian cell incubator (37°C,  $\geq 70\%$  humidity, 5% CO<sub>2</sub>) for 4 - 6 hours.

**6.)** Near the end of the pre-incubation period remove **Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.

**7.) Prepare the Test Compound and Reference Compound treatment media at the desired final assay concentrations:** Use CSM to prepare an appropriate dilution series of the reference and test compound stocks. Prepare all treatment media at the desired final assay concentrations. In *Step 9*, the prepared treatment media will be dispensed at **200  $\mu$ l / well** into the strip-wells. Manage dilution volumes carefully; this assay kit provides **45 ml** of CSM.

NOTE: Total DMSO carried over into assay reactions should not exceed 0.4%.

**a. Agonist-mode assays.** This Assay kit includes a 30 mM stock solution of Rifampicin, the most commonly cited reference agonist of human PXR. The following 7-point treatment series, prepared in serial 3-fold decrements, provides a complete dose-response: 30.0, 10.0, 3.33, 1.11, 0.370, 0.123 and 0.0412  $\mu$ M. Be sure to include 'no treatment', or 'vehicle only', control wells. **APPENDIX 1** provides an example for generating such a dilution series.

~ or ~

**b. Antagonist-mode assays.** When setting antagonist assays, first supplement a bulk volume of CSM with the challenge agonist (rifampicin) to achieve the desired final assay-concentration (refer to "*A word about antagonist-mode assay setup*", pg. 7). The agonist-supplemented CSM is then used to generate dilutions of test compound stocks to achieve their final assay concentrations.

**8.)** At the end of the 4-6 hr pre-culture period, discard the pre-culture media. Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using an 8-pin manifold (*e.g.*, Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus. Do *not* touch the well bottoms or run the tip of the aspiration device around the bottom circumference of the assay wells. Such practices will result in destruction of the cells and greatly increased well-to-well variability.

**9.)** Dispense **200  $\mu$ l / well** of each prepared treatment media into the assay plate.

**10.)** Transfer the assay plate into a cell culture incubator for 22 - 24 hours.

NOTE: Ensure a high-humidity ( $\geq 70\%$ ) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

**11.)** For greater convenience on *Day 2*, retrieve the appropriate number of vials of **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

**DAY 2 Assay Protocol:** Subsequent manipulations do *not* require special regard for aseptic technique and may be performed on a bench top.

**12.)** 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature.

*NOTE:* Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

**13.)** Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.

**14.)** *Immediately before proceeding to Step 15:* To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.

**15.)** Following 22 - 24 hours incubation in treatment media, remove media contents from each well of the assay plate (as before in *Step 8*).

**16.)** Add 100 µl of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes following the addition of LDR. Do not shake the assay plate during this period.

**17.)** Quantify luminescence.

## V. Related Products

| Product No.                                     | Product Descriptions                                                                                                          |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| <b>Human PXR Assay Kit Products</b>             |                                                                                                                               |
| IB07001-32                                      | 3x 32 Human PXR assays; strip-wells in 96-well plate frame                                                                    |
| IB07001                                         | 1x 96-well format Human PXR assays                                                                                            |
| IB07002                                         | 1x 384-well format Human PXR assays                                                                                           |
| <b>Rat PXR Assay Kit Products</b>               |                                                                                                                               |
| R07001-32                                       | 3x 32 Rat PXR assays; strip-wells in 96-well plate frame                                                                      |
| R07001                                          | 1x 96-well format Rat PXR assays                                                                                              |
| <b>Mouse PXR Assay Kit Products</b>             |                                                                                                                               |
| M07001-32                                       | 3x 32 Mouse PXR assays; strip-wells in 96-well plate frame                                                                    |
| M07001                                          | 1x 96-well format Mouse PXR assays                                                                                            |
| <b>Dog PXR Assay Kit Products</b>               |                                                                                                                               |
| D07001-32                                       | 3x 32 Dog PXR assays; strip-wells in 96-well plate frame                                                                      |
| D07001                                          | 1x 96-well format Dog PXR assays                                                                                              |
| <b>Cynomolgus Monkey PXR Assay Kit Products</b> |                                                                                                                               |
| C07001-32                                       | 3x 32 Cyn Monkey PXR assays; strip-wells in 96-well plate frame                                                               |
| C07001                                          | 1x 96-well format Cyn Monkey PXR assays                                                                                       |
| <b>LIVE Cell Multiplex (LCM) Assay Products</b> |                                                                                                                               |
| LCM-01                                          | Reagent volumes sufficient to perform <b>96</b> Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats |
| LCM-05                                          | Reagent in <b>5x bulk volume</b> to perform <b>480</b> Live Cell Assays contained in 5 x 96-well assay plates                 |
| LCM-10                                          | Reagent in <b>10x bulk volume</b> to perform <b>960</b> Live Cell Assays contained in 10 x 96-well assay plates               |

Please refer to INDIGO Biosciences website for updated product offerings.

**[www.indigobiosciences.com](http://www.indigobiosciences.com)**

## VI. Limited Use Disclosures

Products offered by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

“CryoMite” is a Trademark <sup>TM</sup> of INDIGO Biosciences, Inc. (State College, PA, USA).

Product prices, availability, specifications, claims and technical protocols are subject to change without prior notice. The printed Technical Manual provided in the kit box will always be the most currently updated version.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All rights reserved.

## APPENDIX 1

Example scheme for the serial dilution of Rifampicin reference agonist, and the setup of a Human PXR dose-response assay.

